PD-L1 testing as a way of personalizing the treatment of non-small cell lung cancer-Reference-Cited by-同舟云学术

PD-L1 testing as a way of personalizing the treatment of non-small cell lung cancer

Published:2019-09-26 Issue:5-6 Volume: Page:40-45
ISSN:2706-8803
Container-title:Likarska sprava
language:
Short-container-title:Lik. sprava

Author:

Moskalenko Yu. V.,Vуnnуchenko I. О.,Smorodska O. M.,Vynnychenko O. I.,Moskalenko R. A

Abstract

Lung cancer is one of the main causes of death from malignant neoplasm all around the world. For the purpose of personalized treatment immunohistochemical determination of specific proteins (biomarkers) presence in tissues and biological fluids is needed. Today management of patients with lung cancer is directly associated with determination of genes mutations: EGFR, ALK, ROS1 and rate of PD-L1 receptors expression. Depending on the PD-L1 expression level blockers of these receptors can be used as the first, supportive and second / third line therapy. As the first line of therapy for patients with high expression level of PD-L1 (≥ 50 % TPS) Pemblizomab is recommended, while for patients with moderate levels (PD-L1 1 – 49% TPS) PD-L1 blockers can be used only as a second / third line of therapy. In numerous clinical trials efficiency and safety of Pemrolizumab, Nivolumab and Atezolizumab have been proved. Testing of Avelumab, Durvalumab, as well as combined drugs – Ipilimumab and Tremilimumb are still going on.

Publisher

LLC Information and Research Center Likarska Sprava

Subject

General Medicine

Reference17 articles.

1. Antonia S., Goldberg S. B., Balmanoukian A. et al. Safety and antitumour activity of durvalumab plus tremilimumab in non-small-cell lung cancer: multicentre, phase 1b study // Lancet Oncol. – 2016. – Vol. 17, N 3. – P. 299–308.

2. Antonia S. J., Lopez-Martin J. A., Bendell J. et al. Nivolumab alone and Nivolumab plus ipilimumab in reccurent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase ½ trial // Lancet Oncol. – 2016. – Vol. 17, N 7. – P. 883–895.

3. Brahmer J., Reckamp K. L., Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer // N. Engl. J. Med. – 2015. – Vol. 373, N 2. – P. 123–135.

4. Büttner R., Gosney J. R., Skov B. G. et al. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer // J. Clin. Oncol. – 2017. – Vol. 35, N 34. – P. 3867–3876.

5. Caicun Zhou, Yi-Long Wu, Gongyan Chen et al. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer // J. Clin. Oncol. – 2015. – Vol. 33, N 19. – P. 2197–2203.